Speaker(s): 

Brianna Bressler, Pharmacy Intern Technician, Staff Member, Geisinger - has nothing to disclose.

Elayna Haring, Pharmacy Intern Technician, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Sarah F. Hale, PharmD, BCPPS, Director of Pharmacy, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Identify the antibiotics that are associated with a higher risk of Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). 
• Recognize the importance of creating personalized antibiotic regimens based on patient specific factors such as gender, infection site, and indication.
• Define the role of cariprazine as an adjunct atypical antipsychotic therapy in patients with major depressive disorder (MDD) who have had inadequate response to antidepressants alone. 
• Relate the primary and secondary efficacy outcomes to clinically relevant utilizations in patient care settings. 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brian Simpkins, PharmD, Jessica Milheim, CPhT, Clara Bishay, PharmD, and Simran Kaur, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.